Wellbeing Magazine on MSN

The enzymatic gap: Why your gut might be missing the right tools for digestion

If you've been struggling with bloating, gas, or cramping after meals and have gone down the rabbit hole of low-FODMAP diets ...
Medindia

Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)

In addition to meeting the primary endpoint of non-inferiority for overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to 78.5% ...

Soaked almonds vs dry almonds: Which is healthier?

A pale, soft, creamy beige nut with a tan brown skin — almonds meet every criterion there is to be called a bite-sized ...

Weight loss GLP-1 drugs craze drives new packages with diagnostics, lifestyle coaching, and drug delivery

The executives of the companies say by pairing weight-loss drugs such as semaglutide (Wegovy) and tirzepatide (Mounjaro) with ...

Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in …

Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca ...
PharmiWeb

U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical ...

The U.S. FDA assigned a target action date of April 8, 2026PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #FDA--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA ...

From gummies to capsules – I tried three supplements that can help with bloating

THE run-up to Christmas can be fun, but the bloating and discomfort that can go with it isn’t. This is caused by overeating, ...

Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

Coherus Oncology, Inc. (NASDAQ: CHRS) today announced compelling six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 trial evaluating LOQTORZI® (toripalimab-tpzi) plus ...